Frost & Sullivan

AUGUST 29, 2024

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% However, the pharma/biopharma industry overall shows stagnant R&D activity. growth from 2023 to 2024. increase from 2022. Total R&D expenditure is approximately $276.81

Biopharma 52

Biopharma Biotechnology Contract research organization Utilities 52

Frost & Sullivan

APRIL 25, 2023

April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. years, to become a truly global company with a diverse mix of public sector and biopharma clients. SAN ANTONIO, TX.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Biotechnology Contract research organization 52

Frost & Sullivan

MAY 9, 2025

The Expanding Role of Clinical Contract Peripheral Services As the pharmaceutical and biopharma industries recalibrate after the COVID-19 pandemic, clinical trial outsourcing has surged, creating significant opportunities for contract research organizations (CROs). The global CRO industry, valued at $66.39 billion by 2030.

Mergers and acquisition activities 52

Mergers and acquisition activities Biopharma Biotechnology Biotech 52

Frost & Sullivan

JANUARY 23, 2025

While 2024 saw a 41% decline in aggregate deal value , falling from $222 billion in 2023 to $130 billion, 2025 is poised for a rebound. The post JP Morgan Healthcare Conference 2025: Key Growth Opportunities Shaping the Future of Pharma and Biotechnology appeared first on Frost & Sullivan.

Biotechnology 52

Biotechnology Mergers and acquisition activities Biotech Biopharma 52